Literature DB >> 20922501

VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior.

Illana Gozes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20922501     DOI： 10.1007/s12031-010-9456-4

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


× No keyword cloud information.
  36 in total

1.  Vasoactive intestinal peptide mRNA and immunoreactivity are decreased in fetal alcohol syndrome model.

Authors:  Catherine Y Spong; Jonathan Auth; Joy Vink; Katie Goodwin; Daniel T Abebe; Joanna M Hill; Douglas E Brenneman
Journal:  Regul Pept       Date:  2002-10-15

2.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

Authors:  I Gozes; S K McCune; L Jacobson; D Warren; T W Moody; M Fridkin; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

3.  Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia.

Authors:  Efrat Dresner; Galila Agam; Illana Gozes
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-03       Impact factor: 4.600

4.  Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.

Authors:  I Gozes; G Lilling; R Glazer; A Ticher; I E Ashkenazi; A Davidson; S Rubinraut; M Fridkin; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  1995-04       Impact factor: 4.030

5.  Molecular biology of learning: modulation of transmitter release.

Authors:  E R Kandel; J H Schwartz
Journal:  Science       Date:  1982-10-29       Impact factor: 47.728

6.  Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist.

Authors:  J R Glowa; L V Panlilio; D E Brenneman; I Gozes; M Fridkin; J M Hill
Journal:  Brain Res       Date:  1992-01-20       Impact factor: 3.252

7.  Cloning and characterization of the human activity-dependent neuroprotective protein.

Authors:  R Zamostiano; A Pinhasov; E Gelber; R A Steingart; E Seroussi; E Giladi; M Bassan; Y Wollman; H J Eyre; J C Mulley; D E Brenneman; I Gozes
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

8.  Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.

Authors:  Margalit Zusev; Illana Gozes
Journal:  Regul Pept       Date:  2004-12-15

Review 9.  NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

Authors:  Illana Gozes; Bruce H Morimoto; Jacqueline Tiong; Anthony Fox; Karole Sutherland; David Dangoor; Miriam Holser-Cochav; Karin Vered; Paul Newton; Paul S Aisen; Yasuji Matsuoka; Christopher H van Dyck; Leon Thal
Journal:  CNS Drug Rev       Date:  2005

10.  A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Authors:  Yasuji Matsuoka; Yan Jouroukhin; Audrey J Gray; Li Ma; Chiho Hirata-Fukae; Hui-Fang Li; Li Feng; Laurent Lecanu; Benjamin R Walker; Emmanuel Planel; Ottavio Arancio; Illana Gozes; Paul S Aisen
Journal:  J Pharmacol Exp Ther       Date:  2008-01-16       Impact factor: 4.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.